<DOC>
	<DOCNO>NCT01223443</DOCNO>
	<brief_summary>Hypothesis : Sealing moderate SVG lesion paclitaxel-eluting stent reduce cardiac event ( death , myocardial infarction , target vessel revascularization ) duration follow-up . Primary objective : To evaluate efficacy stenting moderate SVG lesion paclitaxel-eluting stent reduce first occurrence composite cardiac death , myocardial infarction repeat revascularization relate target SVG duration follow-up ( minimun 2-year follow-up .</brief_summary>
	<brief_title>Sealing Moderate Coronary Saphenous VEin Graft Lesions With Paclitaxel-Eluting Stents</brief_title>
	<detailed_description>This prospective , multicenter , randomize study assess efficacy stenting moderate SVG lesion ( 30 % 60 % visual estimation ) paclitaxel-eluting stent prevention SVG atherosclerosis progression cardiac event follow-up . Patients previous coronary bypass surgery SVG implantation undergo coronary angiography clinical indication screen . If patient moderate lesion level SVGs includable study . After inclusion , patient randomize either stenting moderate SVG lesion taxus stent standard medical treatment . Following procedure , patient follow-up visit telephone clinic 30 day , 180 day , 1 year , yearly common study end date . The duration study approximately 4 year minimun 2-year follow-up .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Clinical indication cardiac catheterization SVG angiography 2 . Presence least one SVG lesion 30 % 60 % diameter stenosis , visual estimation , culprit lesion* responsible clinical syndrome patient *If target lesion locate SVG culprit lesion ( present ) least 4 cm far stented segment ) 3 . Written inform consent 1 . Patient &lt; 18 year old 2 . Ejection fraction &lt; 30 % 3 . Renal insufficiency creatinine &gt; 200 μmol/l 4 . Presence 2 moderate SVG stenoses single SVG significant diffuse SVG disease define disease cover half length SVG 5 . Presence 2 SVGs moderate SVG stenoses 6 . Unsuccessful angioplasty ( residual stenosis &gt; 30 % and/or TIMI flow &lt; 3 ) lesion treat procedure ( culprit lesion treat patient randomization ) 7 . Any significant complication occur angioplasty culprit lesion ( ) procedure 8 . SVG lesion locate distal anastomosis 9 . SVG lesion locate proximal anastomosis ( lesion length &lt; 5 mm SVG ostium ) 10 . Lesion length &gt; 25 mm 11 . SVGs ≤ 3 year ago 12 . Cardiogenic shock 13 . Remaining coronary SVG lesion ( ) treatment ( PCI CABG ) plan within follow year 14 . Pregnancy 15 . Contraindication aspirin and/or thienopyridine/ticagrelor treatment 16 . Allergy paclitaxel 17 . Any disease limiting lifeexpectancy ( less 2 year ) 18 . Need chronic anticoagulation treatment 19 . Definite presence high suspicion thrombus ulceration target lesion 20 . Target lesion locate SVG culprit lesion ( present ) distance target lesion proximal distal part stent implant culprit lesion &lt; 4 cm 21 . Vein graft diameter &lt; 2.5 mm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Coronary Artery Bypass Grafting</keyword>
	<keyword>Drug Eluting Stent</keyword>
	<keyword>Saphenous Vein Graft</keyword>
</DOC>